Structure Therapeutics Inc GPCR
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-02-03 |
| Shares Out. | 213,220,000 |
| Website | structuretx.com/ ↗ |
| Phone | 16504571978 |
| Employees | 233 |
| Net Income | -$76.0M |
| Free Cash Flow | -$159.2M |
| Total Assets | $1.51B |
| Total Liabilities | $61.0M |
| Equity | $1.45B |
About Structure Therapeutics Inc
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Structure Therapeutics Inc is a publicly traded company under the ticker symbol GPCR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
24 analysts (2026-07-01)